Literature DB >> 29024243

Low clinical conversion rate in clinically isolated syndrome patients - diagnostic benefit of McDonald 2010 criteria?

S C Rosenkranz1,2, B Kaulen1,2, A Neuhaus3, S Siemonsen4, S Köpke5, M Daumer3, J-P Stellmann1,2, C Heesen1,2.   

Abstract

BACKGROUND AND
PURPOSE: New diagnostic criteria of multiple sclerosis (MS) increase the number of patients being diagnosed with MS whilst a substantial part might not convert to clinically definite MS (CDMS). The diagnostic accuracy of the McDonald 2005 and 2010 criteria for conversion to CDMS was evaluated in an unselected cohort of patients in whom an MS diagnostic work-up was decided.
METHODS: Clinical, magnetic resonance imaging and cerebrospinal fluid data were analysed for all patients who presented with symptoms suspicious for MS at the university based MS outpatient clinic between 2006 and 2010 (n = 165).
RESULTS: Follow-up was available for 131 patients. During the mean follow-up period of 2 years, 19% of patients developed CDMS whereas 64% of the patients fulfilling McDonald 2010 criteria did not convert to CDMS.
CONCLUSION: The low clinical conversion rate indicates that the new diagnostic criteria may increase the incidence of MS cases with a less active disease course.
© 2017 EAN.

Entities:  

Keywords:  zzm321990CDMSzzm321990; zzm321990CISzzm321990; McDonald 2010; conversion rate; diagnostic accuracy study

Mesh:

Year:  2017        PMID: 29024243     DOI: 10.1111/ene.13476

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  4 in total

Review 1.  Misdiagnosis of multiple sclerosis: Impact of the 2017 McDonald criteria on clinical practice.

Authors:  Andrew J Solomon; Robert T Naismith; Anne H Cross
Journal:  Neurology       Date:  2018-10-31       Impact factor: 9.910

2.  Application of the 2017 Revised McDonald Criteria for Multiple Sclerosis to Patients With a Typical Clinically Isolated Syndrome.

Authors:  Roos M van der Vuurst de Vries; Julia Y Mescheriakova; Yu Yi M Wong; Tessel F Runia; Naghmeh Jafari; Johnny P Samijn; Janet W K de Beukelaar; Beatrijs H A Wokke; Theodora A M Siepman; Rogier Q Hintzen
Journal:  JAMA Neurol       Date:  2018-11-01       Impact factor: 18.302

Review 3.  Short- and long-term clinical outcomes of use of beta-interferon or glatiramer acetate for people with clinically isolated syndrome: a systematic review of randomised controlled trials and network meta-analysis.

Authors:  X Armoiry; A Kan; G J Melendez-Torres; R Court; P Sutcliffe; P Auguste; J Madan; C Counsell; A Clarke
Journal:  J Neurol       Date:  2018-01-22       Impact factor: 4.849

4.  Study protocol for a randomised controlled trial of a web-based behavioural lifestyle programme for emPOWERment in early Multiple Sclerosis (POWER@MS1).

Authors:  Nicole Krause; Karin Riemann-Lorenz; Tanja Steffen; Anne Christin Rahn; Jana Pöttgen; Jan-Patrick Stellmann; Sascha Köpke; Tim Friede; Andrea Icks; Markus Vomhof; Herbert Temmes; Markus van de Loo; Stefan M Gold; Christoph Heesen
Journal:  BMJ Open       Date:  2021-02-16       Impact factor: 2.692

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.